Stocktoria
BIOMARIN PHARMACEUTICAL INC BMRN
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 1999-07-23
BIOMARIN PHARMACEUTICAL INC statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | 12.7% | 17.0% | 7.7% | 7.7% | -4.5% |
| Net margin | 10.8% | 15.0% | 6.9% | 6.8% | -3.5% |
| FCF margin | 22.5% | 17.1% | 2.6% | 2.6% | 11.3% |
| Return on assets | 4.6% | 6.1% | 2.5% | 2.2% | -1.1% |
| Return on equity | 5.7% | 7.5% | 3.4% | 3.1% | -1.5% |
| Debt / equity | 0.10× | — | — | — | — |
| Current ratio | 5.21 | 5.33 | 2.51 | 4.67 | 4.16 |
| Revenue growth | 12.9% | 18.0% | 15.4% | 13.5% | -0.8% |
Source: SEC EDGAR filings · CIK 0001048477 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.